262 related articles for article (PubMed ID: 21681652)
1. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
3. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
[TBL] [Abstract][Full Text] [Related]
4. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
6. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
7. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N
J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517
[TBL] [Abstract][Full Text] [Related]
10. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
11. A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
Williams L; Malhotra Y; Murante B; Laverty S; Cook S; Topa D; Hardy D; Wang H; Gigliotti F
J Pediatr; 2013 Apr; 162(4):857-61. PubMed ID: 23092529
[TBL] [Abstract][Full Text] [Related]
12. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
13. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
14. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
17. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
Granet DB; Dorfman M; Stroman D; Cockrum P
J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
[TBL] [Abstract][Full Text] [Related]
18. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis.
Belfort R; Gabriel L; Martins Bispo PJ; Muccioli C; Zacharias Serapicos PC; Clark L; Bell B; Bartell J; Stroman DW; Höfling-Lima AL
Adv Ther; 2012 May; 29(5):416-26. PubMed ID: 22562783
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]